Role of Indoor Pollutants on House Dust Mite Allergic Asthma
NCT ID: NCT01019291
Last Updated: 2015-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlled Human Exposure to Indoor Air, Dust and Ozone
NCT02017782
Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction
NCT02017431
THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins
NCT07271381
Effects of Co-Exposure to Air Pollution and Allergen
NCT01792232
National Survey of Lead and Allergen Hazards in Housing
NCT00339573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NO2
NO2 400 µg/m3
Formaldehyde and NO2 (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Formaldehyde
Formaldehyde 100 µg/m3
Formaldehyde and NO2 (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
NO2 + Formaldehyde
mixture of Formaldehyde and NO2
Formaldehyde and NO2 (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Placebo
Placebo (Exposure to indoor pollutants)
Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Formaldehyde and NO2 (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Placebo (Exposure to indoor pollutants)
Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of intermittent HDM allergic asthma-FEV1 \> 80%
* Non smokers or smokers with smoking \< 10 PY
Exclusion Criteria
* Allergic to pets and pets at home
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hôpitaux Universitaires de Strasbourg
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frederic DE BLAY, MD
Role: PRINCIPAL_INVESTIGATOR
Service de Pneumologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unité de Pneumologie, d'Allergologie et de Pathologie Respiratoire de l'Environnement, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3965
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.